Publications by authors named "Mary Hanlon"

Claim this Profile
N
NIH Precision Medicine Initiative: Implications for Diabetes Research.
Judith E Fradkin, Mary C Hanlon, Griffin P Rodgers

Diabetes Care· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Celebrating 30 years of research accomplishments of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
Judith E Fradkin, Catherine C Cowie, Mary C Hanlon, Griffin P Rodgers

Diabetes· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Curt D Haffner, Caroline J Diaz, Aaron B Miller, Robert A Reid, Kevin P Madauss, Mary H Hanlon

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Richard Hazen, Robert Harvey, Robert Ferris, Charles Craig, Phillip Yates, Mary Hanlon

Antimicrob Agents Chemother· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
John F Miller, C Webster Andrews, Michael Brieger, Eric S Furfine, Michael R Hale, Mary H Hanlon

Bioorg Med Chem Lett· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Mary H Hanlon, David J T Porter, Eric S Furfine, Andrew Spaltenstein, H Luke Carter

Biochemistry· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
John F Miller, Eric S Furfine, Mary H Hanlon, Richard J Hazen, John A Ray

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A conserved catalytic residue in the ubiquitin-conjugating enzyme family.
Pei-Ying Wu, Mary Hanlon, Michael Eddins, Colleen Tsui, Richard S Rogers

EMBO J· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of HDM2 activity by the ribosomal protein L11.
Marion A E Lohrum, Robert L Ludwig, Michael H G Kubbutat, Mary Hanlon, Karen H Vousden

Cancer Cell· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Michael F Maguire, Rosario Guinea, Philip Griffin, Sarah Macmanus, Robert C Elston, Mary H Hanlon

J Virol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 protease: characterization of a catalytically competent enzyme-substrate intermediate.
David J T Porter, Mary H Hanlon, Eric S Furfine

Biochemistry· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis